CAII-Copper Compositions Enhancing Nitrite Reductase Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of carbonic anhydrase II's (CAII) role in diseases is limited, particularly regarding its nitrite reductase activity and its potential in treating conditions like hypertension and heart diseases, where existing treatments are inadequate in harnessing its vasodilation effects.
Innovation Solution
Development of compositions comprising CAII bound to copper, specifically with His94, His96, and His119, and CAII inhibitors like sulfonamide-based compounds to enhance nitrite reductase activity, which can be administered to treat conditions responsive to vasodilation such as hypertension and heart conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAII is bound to copper to enhance nitrite reductase activity, then therapeutic efficacy for hypertension and heart diseases is improved, but understanding and control of the enzyme's activity is limited
Solution Approach 1:
The patent uses sulfonamide-based compounds as intermediary molecules that bind to CAII and modulate its activity. These compounds serve as mediators between the administered CAII-copper composition and the target disease processes, allowing controlled enhancement of nitrite reductase activity while maintaining safety and efficacy profiles.
Solution Approach 2:
The patent employs sulfonamide compounds that induce parameter changes in CAII activity by binding to specific sites on the enzyme. This binding alters the enzyme's catalytic properties, specifically enhancing nitrite reductase activity while maintaining other physiological functions, thereby achieving therapeutic effects with controlled parameter modification.
2Reliability
If sulfonamide-based CAII inhibitors are administered to enhance nitrite reductase activity, then treatment effectiveness for vasodilation-responsive conditions is improved, but drug interaction complexity increases
Solution Approach 1:
The sulfonamide-based compounds described in the patent exhibit multi-functionality by simultaneously acting as CAII modulators and potentially interacting with other therapeutic agents. These compounds can enhance nitrite reductase activity while also providing additional pharmacological effects, reducing the need for multiple separate medications and simplifying overall treatment regimens.
Solution Approach 2:
The CAII-sulfonamide complex exhibits self-service properties by autonomously enhancing nitrite reductase activity without requiring additional complex delivery systems or auxiliary compounds. The sulfonamide-bound CAII self-regulates its catalytic activity to produce therapeutic effects, reducing the complexity of drug delivery and monitoring systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CAII-copper compositions and inhibitors significantly increase nitrite reductase activity, providing effective treatment options for conditions like hypertension and heart diseases by promoting vasodilation, improving drug efficacy and duration of action for NSAIDs like aspirin.
Implementation Method 1
carbonic anhydrase, which is found in blood, has nitrite reductase activity when bound to copper in a particular configuration. Nitrite reductase activity is useful for treating conditions such as hypertension, heart conditions, muscular atrophy, or any condition that can be relieved by causing vasodilation.
Implementation Method 2
His94, His96, and His119 of the CAII corresponding to amino acids in SEQ ID NO: 1 are bound to a copper atom, and His4, His3, and Ser2 of the CAII corresponding to amino acids in SEQ ID NO: 1 are bound to a copper atom.
Data Source
AI summary
Provided herein are compositions of carbonic anhydrase and inhibitors thereof for the treatment of subjects with certain conditions such as heart disease.